Disagreement Between Two Kidney Function Tests Predicts Serious Health Problems

NEW YORK and HOUSTON, Nov. 7, 2025 /PRNewswire/ -- A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and death, a new study shows.

Health care providers for decades have measured blood levels of the molecule creatinine to track the rate at which kidneys filter waste from muscle breakdown in the bloodstream. According to more recent guidelines, levels of cystatin C, a small protein made by all cells in the body, can also be used to measure kidney function. Since these two tests are influenced by different factors — including some related to disease or aging — using both markers together can provide a better measure of kidney function and risk of organ failure than either one alone.

Led by NYU Langone Health researchers, the new work reveals that many people, especially those who are sick, often have a large gap between the two readings, which may be a signal of future disease. Specifically, the global study shows that more than a third of hospitalized participants had a cystatin C-based readout of kidney function that was at least 30% lower than one based on their creatinine levels.

"Our findings highlight the importance of measuring both creatinine and cystatin C to gain a true understanding of how well the kidneys are working, particularly among older and sicker adults," said study co-corresponding author Morgan Grams, MD, PhD. "Evaluating both biomarkers may identify far more people with poor kidney function, and earlier in the disease process, by covering the blind spots that go with either test."

The study is publishing online Nov. 7 in the Journal of the American Medical Association and is simultaneously being presented at the American Society of Nephrology's annual Kidney Week conference.

Beyond detecting signs of disease, assessing patients' kidney function is important for calculating the appropriate dosage for cancer medicines, antibiotics, and many other drugs, says Grams, the Susan and Morris Mark Professor of Medicine at the NYU Grossman School of Medicine.

During another investigation, the results of which were published the same day, the same research team found that a record number of people worldwide have chronic kidney disease, which is now the ninth leading cause of death globally. Having new ways to spot the condition early can help ensure that patients receive swift treatment and avoid more dramatic interventions such as dialysis and organ transplantation, says Grams, who is also a professor in the Department of Population Health at NYU Grossman School of Medicine.

For the recent investigation, the research team analyzed health care records, blood tests, and demographic data collected from 860,966 men and women of a half-dozen nationalities. All participants had their creatinine and cystatin C levels measured on the same day and received follow-ups 11 years later on average. The team considered factors unrelated to kidney function that influence the biomarkers' readings, such as smoking, obesity, and history of cancer.

Performed as part of the international Chronic Kidney Disease Prognosis Consortium, the study is the largest to date to explore differences between the two tests and whether they may signal potential health problems, the authors say. Established to better understand and treat the condition, the consortium provides evidence for global definitions of chronic kidney disease and related health risks.

According to the new findings, those whose cystatin C-based measures of kidney filtration were at least 30% lower than their creatinine-based measures were at higher risk for death, heart disease, and heart failure than those who had a smaller difference between the two metrics. The former group was also more likely to be diagnosed with severe chronic kidney disease that required dialysis or an organ transplant. The same was found for 11% of outpatients and seemingly healthy volunteers.

Grams notes that while cystatin C testing was first recommended in 2012 by the international organization Kidney Disease — Improving Global Outcomes, a 2019 survey revealed that less than 10% of clinical laboratories in the United States performed it in-house. The two largest laboratories, Quest Diagnostics and Labcorp, now offer the test.

"These results underscore the need for physicians to take advantage of the fact that more hospitals and health care providers are starting to offer cystatin C testing," said study co-corresponding author Josef Coresh, MD, PhD, director of NYU Langone's Optimal Aging Institute. "Physicians might otherwise miss out on valuable information about their patients' well-being and future medical concerns."

Coresh, who is also the Terry and Mel Karmazin Professor of Population Health at NYU Grossman School of Medicine, cautions that among the hospitalized Americans in the study, less than 1% were tested for cystatin C.

Funding for the study was provided by National Institutes of Health grant R01DK100446 and by the National Kidney Foundation.

Michelle Estrella, MD, MHS, at the University of California, San Francisco, is the study's first author. Kai-Uwe Eckardt, MD, at Charite-Universitatsmedizin Berlin in Germany, is the study last author. Along with Grams and Coresh, who are co-leaders of the Chronic Kidney Disease Prognosis Consortium, NYU Langone researchers involved in the study are Shoshana Ballew, PhD; Yingying Sang, MS; and Aditya Surapaneni, PhD. Other study co-investigators are Teresa Chen, MD, MHS, and Michael Shlipak, MD, MPH, at the University of California, San Francisco; Natalia Alencar de Pinho, PhD, at Paris-Saclay University in Villejuif, France; Johan Arnlov, MD, PhD, at Dalarna University in Falun, Sweden; Hermann Brenner, MD, MPH, at Heidelberg University in Germany; Juan-Jesus Carrero, PharmD, PhD, at Karolinska Institutet in Huddinge, Sweden; Debbie Cohen, MBBCh, at the University of Pennsylvania in Philadelphia; Mary Cushman, MD, MSc, at the University of Vermont in Burlington; Ron Gansevoort, MD, PhD, at the University of Groningen in the Netherlands; Shih-Jen Hwang, PhD, at the National Institutes of Health in Bethesda, Maryland; Lesley Inker, MD, and Andrew Levey, MD, at Tufts Medical Center in Boston; Joachim Ix, MD, at the University of California, San Diego; Keiko Kabasawa, MD, PhD, MPH, at Niigata University in Japan; Tsuneo Konta, MD, PhD, at Yamagata University in Japan; Jennifer Lees, PhD, at the University of Glasgow in Scotland; Kevan Polkinghorne, PhD, at Monash University in Melbourne, Australia; Robin Vernooij, MS, at Utrecht University in the Netherlands; David Wheeler, MD, at University College London; and Ashok Kumar Yadav, PhD, at the Postgraduate Institute of Medical Education and Research in Chandigarh, India.

About NYU Langone Health
NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc. has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation for four years in a row, and U.S. News & World Report recently ranked four of its clinical specialties number one in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.

Media Inquiries
Shira Polan
Phone: 212-404-4279
[email protected]

SOURCE NYU Grossman School of Medicine and NYU Langone Health